Search
Search Results
-
Neoangiogenesis Inhibitors (Sunitinib, Sorafenib, and Bevacizumab)
As a result of clinical studies, interstitial pneumonia is listed among important toxic events associated with the use of neoangiogenesis inhibitors....
-
Bevacizumab (Avastin)
This chapter reviews the neuroimaging features of the potential effects of bevacizumab use.
-
Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
BackgroundBAT1706 is a proposed biosimilar of bevacizumab, a vascular endothelial growth factor A (VEGF-A)-targeting biologic used to treat several...
-
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
BackgroundGlioblastoma (GBM), the most lethal primary brain tumor, has limited treatment options upon recurrence after chemoradiation and...
-
Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer
BackgroundBevacizumab-awwb was the first biosimilar approved for cancer treatment in the USA. Limited information is available on the real-world...
-
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
The combination of re-irradiation and bevacizumab has emerged as a potential therapeutic strategy for patients experiencing their first glioblastoma...
-
Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
Background and ObjectiveHepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide, especially in China. According...
-
Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma
IntroductionGlioblastoma (GBM) is the most common central nervous system malignancy in adults. Despite decades of developments in surgical...
-
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors
BackgroundThe combination of paclitaxel to platinum remains the backbone of therapy in patients with advanced Mullerian tumors. In patients with...
-
Secondary spontaneous pneumothorax during chemotherapy with bevacizumab for cervical cancer: a case report and literature review
Secondary spontaneous pneumothorax (SSP) due to bevacizumab has been reported in other malignancies but not in cervical cancer. We present the case...
-
Bevacizumab improved prognosis for advanced EGFR-mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy
ObjectiveThis study aimed to determine whether the combined use of bevacizumab could improve overall survival (OS) in patients with brain metastasis...
-
Cost-effectiveness analysis of bevacizumab for cerebral radiation necrosis treatment based on real-world utility value in China
BackgroundBevacizumab shows superior efficacy in cerebral radiation necrosis (CRN) therapy, but its economic burden remains heavy due to the high...
-
Comparison of intravitreal bevacizumab monotherapy and combined laser photocoagulation and intravitreal bevacizumab therapy in the same session in the treatment of aggressive retinopathy of prematurity
PurposeTo compare the results of intravitreal bevacizumab (IVB) monotherapy and combined intravitreal bevacizumab and laser photocoagulation (LPC)...
-
Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)
BackgroundPF-06439535 (bevacizumab-bvzr; Zirabev ® ) is a biosimilar of bevacizumab reference product (RP; Avastin ® ). This study describes the...
-
Combination of pemetrexed with bevacizumab for non-small-cell lung cancer: a meta-analysis study
BackgroundCombining pemetrexed with bevacizumab may have some potential in improving the efficacy in patients with non-small-cell lung cancer...
-
Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors
BackgroundTo date, evidence has been lacking regarding bevacizumab pharmacokinetics in the cerebrospinal fluid (CSF).
ObjectiveThis study assessed...
-
The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab
PurposeBevacizumab has evolved as an integral treatment option for patients with high-grade gliomas. Little is known about clinical risk factors that...
-
Topical Solution for Retinal Delivery: Bevacizumab and Ranibizumab Eye Drops in Anti-Aggregation Formula (AAF) in Rabbits
PurposeWet age-related macular degeneration (AMD) is a blinding retinal disease. Monthly intravitreal anti-VEGF antibody injections of bevacizumab...
-
Machine learning application identifies plasma markers for proteinuria in metastatic colorectal cancer patients treated with Bevacizumab
Background and objectivesProteinuria is a common complication after the application of bevacizumab therapy in patients with metastatic colorectal...
-
Outcomes of systemic bevacizumab in radiation-induced optic neuropathy, case series
PurposeOptic neuropathy is a rare, delayed complication after radiation with no universally accepted treatment modality. We report the outcomes of 6...
